Sight Sciences, Inc. (SGHT) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Sight Sciences, Inc. is an ophthalmic medical device company operating in two segments: Interventional Glaucoma (OMNI Surgical System, SION Surgical Instrument) and Interventional Dry Eye (TearCare System). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $19.7 million | $17.5 million |
| Gross Profit | $17.0 million | $15.1 million |
| Gross Margin | 86.2% | 86.2% |
| Net Loss | $(13.0) million | $(14.2) million |
| Diluted EPS | $(0.24) | $(0.28) |
| Cash and Equivalents | $85.0 million | $108.8 million |
| Total Debt (Principal) | $40.0 million | $40.0 million |
| Operating Cash Flow | $(7.0) million | $(11.6) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 12.5% year-over-year. The Interventional Glaucoma segment grew 7.2% due to higher unit sales and average selling prices. The Interventional Dry Eye segment surged 243.7% driven by increased SmartLid volume following reimbursement progress in late 2025.
- Expense Management: Research and Development (R&D) expenses decreased 42.5% to $2.5 million, attributed to a targeted cost-reduction plan implemented in Q3 2025. Conversely, Selling, General, and Administrative (SG&A) expenses increased 9.5% to $26.8 million, primarily due to a $5.4 million litigation success fee accrued for the Alcon patent infringement case.
- Loss Reduction: Net loss narrowed by 8.3% to $13.0 million, reflecting revenue growth and reduced R&D spend, partially offset by the litigation fee and lower investment income.
Outlook, Risks, and Contingencies
- Litigation Outcome: On April 22, 2026, a final judgment was entered in Sight Sciences' favor against Alcon, awarding $55.4 million in damages and a 10% ongoing royalty on Hydrus revenue. A $5.4 million success fee was accrued in Q1 2026. The judgment is subject to appeal, and two USPTO reexamination proceedings regarding the patents remain pending, creating uncertainty regarding the final collectability of damages.
- Liquidity: The company holds $85.0 million in cash and expects to fund operations for at least the next 12 months. It maintains a $65.0 million credit facility with Hercules Capital, with $40.0 million currently drawn. The interest-only period was extended to February 1, 2027.
- Reimbursement: Continued focus on expanding reimbursement for TearCare products and protecting reimbursement for Interventional Glaucoma products remains a critical strategic priority.
- Forward-Looking Risks: Risks include the outcome of the Alcon appeal and USPTO reexaminations, ability to secure additional financing if needed, and potential impacts of geopolitical tensions on supply chains and tariffs.
Investor Verification Checklist
- Alcon Litigation Status: Verify the current status of the appeal and the two pending USPTO reexamination proceedings to assess the certainty of the $55.4 million award and ongoing royalties.
- Debt Covenants: Confirm continued compliance with minimum cash and revenue covenants under the Hercules Loan Agreement.
- Reimbursement Expansion: Monitor progress on Medicare Administrative Contractor fee schedules for the TearCare procedure (CPT code 0563T) to validate the sustainability of the Dry Eye segment's growth.
- Cash Burn Rate: Review the trajectory of operating cash outflows relative to the $85 million cash balance to ensure the 12-month liquidity runway remains valid.